5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPγS binding in rat hippocampal membranes

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 5-6, 2007, Pages 462-466

  Odagaki, Yuji ^a   Toyoshima, Ryoichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

5 HT1A receptor; Atypical antipsychotics; Clozapine; G protein; Guanosine diphosphate; Intrinsic activity; Nemonapride; Partial agonist

Indexed keywords

ARIPIPRAZOLE; BUFFER; CLOZAPINE; EMONAPRIDE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PEROSPIRONE; QUETIAPINE; SEROTONIN 1A AGONIST; ZIPRASIDONE; BENZAMIDE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; INDOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN 1A RECEPTOR; SULFUR; THIAZOLE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HIPPOCAMPUS; NONHUMAN; RAT; ANIMAL; BINDING COMPETITION; CELL MEMBRANE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BINDING, COMPETITIVE; CELL MEMBRANE; CLOZAPINE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; HIPPOCAMPUS; HUMANS; INDOLES; PIPERAZINES; PYRIDINES; QUINOLONES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SULFUR RADIOISOTOPES; THIAZOLES;

EID: 33947658001     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04595.x     Document Type: Article

References (30)

1. 1A receptor in schizophrenia: A promising target for novel atypical neuroleptics? J. Psychopharmacol. 2001; 15: 37-46.
2. 1A receptors. J. Pharmacol. Exp. Ther. 2000; 295: 853-61.
3. Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J. Clin. Psychopharmacol. 2001; 21: 454-5.
4. Sumiyoshi T, Matsui M, Yamashita I et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J. Clin. Psychopharmacol. 2000; 20: 386-8.
5. Sumiyoshi T, Matsui M, Nohara S et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 2001; 158: 1722-3.
6. 1A agonist, on memory function in schizophrenia. Biol. Psychiatry 2001; 49: 861-8.
7. 1A receptors. Neuropharmacology 1996; 35: 119-21.
8. 1A receptor agonist properties of the antipsychotic, nemonapride: Comparison with bromerguride and clozapine. Eur. J. Pharmacol. 1997; 334: 141-7.
9. 1A receptors expressed in HeLa cells. Eur. J. Pharmacol. 2001; 433: 55-62.
10. 1A receptor. Eur. J. Pharmacol. 2002; 441: 137-40.
11. 35S]GTPγS binding study. Eur. J. Pharmacol. 1998; 355: 245-56.
12. 3H]WAY100,635 binding affinity ratio: Relationship to efficacy for G-protein activation. Eur. J. Pharmacol. 2001; 428: 177-84.
13. 1A receptors in human post-mortem brain. Eur. J. Pharmacol. 1999; 386: 313-15.
14. 1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch. Pharmacol. 2003; 368: 188-99.
15. Newman-Tancredi A, Assié MB, Leduc N, Ormiêre AM, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8: 341-56.
16. 35S]GTPγS binding in rat hippocampal membranes. J. Pharmacol. Sci. 2005; 98: 66 -76. (Erratum, 2005; 98: 190.)
17. 1A receptors. Biog. Amines 2004; 18: 307-17.
18. 35S]GTPγS binding in rat hippocampal membranes. Eur. J. Pharmacol. 1998; 343: 303-12.
19. 1A receptor activation. Eur. J. Pharmacol. 1997; 338: R3-5.
20. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry 2000; 48: 229-37.
21. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001; 76: 1521-31.
22. Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 2005; 315: 265-72.
23. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role in atypical antipsychotic action. J. Neurosci. 2005; 25: 10 831-43.
24. Mori A, Kazamatsuri H, Kaneno S et al. A double-blind comparison of a new benzamide compound YM-09151 with haloperidol in the treatment of schizophrenia. Rinsho Hyoka 1989; 17: 349-77 (in Japanese with English abstract).
25. Kondo T, Ishida M, Tokinaga N et al. Association between side effects of nemonapride and plasma concentrations of the drug and prolactin. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 287-91.
26. Kondo T, Mihara K, Yasui N et al. Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. J. Clin. Psychopharmacol. 2000; 20: 404-9.
27. Satoh K, Someya T, Shibasaki M. Effects of nemonapride on positive and negative symptoms of schizophrenia. Int. Clin. Psychopharmacol. 1996; 11: 279-81.
28. 35S]GTPγS binding in rat cerebral cortex. Eur. J. Pharmacol. 2005; 521: 49-58.
29. Meneses A. 5-HT system and cognition. Neurosci. Biobehav. Rev. 1999; 23: 1111-25.
30. Araki T, Yamasue H, Sumiyoshi T et al. Perospirone in the treatment of schizophrenia: Effect on verbal memory organization. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 204-8.